Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multipotency of Hematopoietic Stem Cells01:19

Multipotency of Hematopoietic Stem Cells

3.1K
The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
3.1K
Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

3.2K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.2K
Renewal of Intestinal Stem Cells01:23

Renewal of Intestinal Stem Cells

2.6K
The intestinal epithelial lining rapidly renews every 4 to 5 days. The renewal is facilitated by intestinal stem cells (ISCs) located at the base of the crypt– a gland located at the bottom of each villus. ISCs divide asymmetrically to form new stem cells and progenitor daughter cells. The daughter cells are called transit-amplifying (TA) cells which move upwards along the crypt and either differentiate into absorptive cells– the enterocytes or secretory cells– including the...
2.6K
iPS Cell Differentiation01:22

iPS Cell Differentiation

2.7K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
2.7K
Somatic to iPS Cell Reprogramming01:29

Somatic to iPS Cell Reprogramming

2.2K
Reprogramming alters the gene expression in somatic cells, transforming them into induced pluripotent stem (iPS) cells over several generations. Scientists can reprogram cells by introducing genes for four transcription factors—Oct4, Sox2, Klf4, and c-Myc (OSKM) by viral or non-viral methods. These factors are also known as Yamanaka factors after Shinya Yamanaka, who first generated iPS cells using mouse skin cells. Yamanaka was awarded the Nobel Prize in Physiology or Medicine in 2012...
2.2K
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

4.0K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Serotype skewing and immune imprinting shape response to the tetravalent dengue virus Qdenga vaccine.

medRxiv : the preprint server for health sciences·2026
Same author

Neutralising antibody responses to MPXV clades Ia, Ib, and IIb after infection or vaccination: a multicountry observational study.

The Lancet. Infectious diseases·2026
Same author

Oromucosal Administration of a Cannabidiol-Enriched Cannabis sp. Extract for 2 Weeks Moderately Reduces Cold Hyperalgesia in Rats With Neuropathic Pain.

European journal of pain (London, England)·2026
Same author

Highly efficient and low-cost single-cell culture platform for unbiased analysis of human memory B cell repertoire and antibody discovery.

Journal of immunology (Baltimore, Md. : 1950)·2025
Same author

Impact of COVID-19 vaccination on symptoms and immune phenotypes in vaccine-naïve individuals with Long COVID.

Communications medicine·2025
Same author

The impact of orthopoxvirus vaccination and Mpox infection on cross-protective immunity: a multicohort observational study.

The Lancet. Microbe·2025

Related Experiment Video

Updated: Jun 27, 2025

Collection of Serum- and Feeder-free Mouse Embryonic Stem Cell-conditioned Medium for a Cell-free Approach
09:32

Collection of Serum- and Feeder-free Mouse Embryonic Stem Cell-conditioned Medium for a Cell-free Approach

Published on: January 8, 2017

10.3K

The Benjamin Button effect on stem cells: Reversing the clock on aging immunity.

Luciana Conde1, Carolina Lucas1

  • 1Department of Immunobiology, Yale University School of Medicine, New Haven, CT, USA.

Science Immunology
|May 3, 2024
PubMed
Summary
This summary is machine-generated.

Antibody therapy targeting myeloid-biased hematopoietic stem cells (my-HSCs) rejuvenates the aged immune system. This approach enhances immune responses in elderly mice.

More Related Videos

Detecting Establishment of Shared Blood Supply in Parabiotic Mice by Caudal Vein Glucose Injection
06:27

Detecting Establishment of Shared Blood Supply in Parabiotic Mice by Caudal Vein Glucose Injection

Published on: February 6, 2020

8.4K
SA-β-Galactosidase-Based Screening Assay for the Identification of Senotherapeutic Drugs
07:39

SA-β-Galactosidase-Based Screening Assay for the Identification of Senotherapeutic Drugs

Published on: June 28, 2019

23.9K

Related Experiment Videos

Last Updated: Jun 27, 2025

Collection of Serum- and Feeder-free Mouse Embryonic Stem Cell-conditioned Medium for a Cell-free Approach
09:32

Collection of Serum- and Feeder-free Mouse Embryonic Stem Cell-conditioned Medium for a Cell-free Approach

Published on: January 8, 2017

10.3K
Detecting Establishment of Shared Blood Supply in Parabiotic Mice by Caudal Vein Glucose Injection
06:27

Detecting Establishment of Shared Blood Supply in Parabiotic Mice by Caudal Vein Glucose Injection

Published on: February 6, 2020

8.4K
SA-β-Galactosidase-Based Screening Assay for the Identification of Senotherapeutic Drugs
07:39

SA-β-Galactosidase-Based Screening Assay for the Identification of Senotherapeutic Drugs

Published on: June 28, 2019

23.9K

Area of Science:

  • Immunology
  • Hematology
  • Aging Research

Background:

  • Immune system function declines with age, leading to reduced efficacy of immune responses.
  • Hematopoietic stem cells (HSCs) show age-related alterations, including a bias towards myeloid lineages (my-HSCs).
  • This myeloid bias is linked to immune dysfunction and inflammation in aging.

Purpose of the Study:

  • To investigate the therapeutic potential of depleting my-HSCs in aged mice.
  • To determine if targeting my-HSCs can rejuvenate the immune system.
  • To assess the impact of my-HSC depletion on immune response efficacy.

Main Methods:

  • Administration of a specific antibody to deplete my-HSCs in aged mice.
  • Flow cytometry and cell sorting to analyze HSC populations and immune cell subsets.
  • Functional assays to evaluate immune responses, such as T cell activation and cytokine production.

Main Results:

  • Successful depletion of myeloid-biased hematopoietic stem cells (my-HSCs) was achieved.
  • Depletion of my-HSCs led to a rejuvenation of the immune system in aged mice.
  • Improved immune responses were observed following my-HSC targeted therapy.

Conclusions:

  • Targeting and depleting my-HSCs is a viable strategy for immune system rejuvenation in aging.
  • This antibody-based therapy holds promise for enhancing immune function in the elderly.
  • Further research into my-HSC-targeted therapies could lead to new treatments for age-related immune decline.